Montréal-based biotech firm KisoJi Biotechnology has raised $57 million CAD to advance its cancer treatment into clinical trials and enhance its AI-driven antibody discovery platform. The Series B round, co-led by Investissement Québec and Lumira Ventures, includes support from Fonds de solidarité FTQ, adMare BioInnovations, and Remiges Ventures.
KisoJi’s flagship therapy, KJ-103, a monoclonal antibody targeting tumour cells, will debut in clinical trials with Cancer Research UK. The funding will also bolster KisoJi’s AI-powered KisoSeek platform, which identifies antibodies for treating cardiometabolic diseases. CEO David Young emphasizes the company’s commitment to advancing life sciences and antibody therapies.
Want to know more? Check out the source code on BetaKit.